7/22/2019 Makri Dou 2009

1/96

...:...

:

:: ..

:, ,

: .

22000099

1

7/22/2019 Makri Dou 2009

2/96

2009,

,

.

.

, , . ,

.

, .

,

.

.

.

.

( Sc, PhD)

,

.

2

7/22/2019 Makri Dou 2009

3/96

..................................................................................................... i

..... ii

.. v

1 : I

1.1 11.2 .... 21.2.1 ... 2

1.2.2

-... 31.2.3 . 41.2.4 ... 5

2: -

2.1 - 72.2 - 9

2.3 - u 10

3:

3.1 . 123.1.1 . 123.1.2 133.1.3 .. 13

3.1.4 143.2 .. 15

3

7/22/2019 Makri Dou 2009

4/96

3.2.1 .. 16

3.3 173.3.1 173.3.2 .. 183.3.3 213.3.4 21

4:

4.1 224.1.1 23

4.1.2 244.2 . 254.3 254.4 . 264.5 .. . 274.6 -. 284.7 . 284.8 .. 304.9 314.10

32

5:

5.1 .345.2 355.2.1 ..36

5.3 385.4 385.4.1 385.4.2 405.4.3 415.4.4 425.5 ; 45

4

7/22/2019 Makri Dou 2009

5/96

6:

6.1 466.1.1 476.2 50

52 .. 52 ... 53 . 56 74 .. 76

:

.. 80

. 86

5

7/22/2019 Makri Dou 2009

6/96

.

( , , ,

, ).

. ,

, .

(ventrogluteal).

,

.

.

,

,

, 81,5%

, 4,5%

0,5% .

.

6

7/22/2019 Makri Dou 2009

7/96

1

1.1

Yaws kala-

azar 1920

(Wyatt HV ,1984).

500 .. , 1880

(Howard-

Jones,1971). ,

(Stokes,Beerman & Ingraham, 1944).

Zelman (1961),

,

. 1957

,

. (Henderson, 1963,1966, 1970, 1972).

'60,

.

'60,

(Dison, 1967 Pitel & Wemett, 1964

Wempe, 1961).

7

7/22/2019 Makri Dou 2009

8/96

1.2

1.2.1

(. 2003).

:

1.1

,

( ) . ,

.

: , ,, .

8

7/22/2019 Makri Dou 2009

9/96

1.2.2 -

.

(. 2003)

:

- :

.

.

.

, ..

- .

:

,

.

,

(C.P.K) (L.D.H).

,

, ,

, .

, , ,

2.

9

7/22/2019 Makri Dou 2009

10/96

,

,

.

1.2-1.3

1.2.3

.

, .

, . (.

2003)

:

- Test .- test, .. mantoux

..

10

7/22/2019 Makri Dou 2009

11/96

1.4

2

. ,

, .

. 10-15

. .

1.2.4

.

2 .

.

. 1-5cc

, , , . ,

45 ,

. (. 2003)

:.

.

.

11

7/22/2019 Makri Dou 2009

12/96

2

1.4

12

7/22/2019 Makri Dou 2009

13/96

2

2.1.

: (1) ,

(2)

(, ,

) .

,

. ,

.

.

. ,

, ,

45 .

(Gichard L. D. et al. 2006).

13

7/22/2019 Makri Dou 2009

14/96

..

.

.

.

. .. .

, ..

.

. (Gichard L. D. et al. 2006).

.

. .

. .

2.1 (Gichard L. D. et al. 2006).

,.

. .

.

,.

.

.

,.

.

14

7/22/2019 Makri Dou 2009

15/96

2.2.

, ,

. ,

. : , ,

.(Gichard L. D. et al. 2006).

2.2:

: ,

, ,

,

. ,

, .

,

.

15

7/22/2019 Makri Dou 2009

16/96

, .

.

, . (Gichard L. D. et al. 2006).

2.3.

, ,

. :

, , .

,

9 ,

9

9 .

,

2.2 (Gichard L. D. et al. 2006).

2.3:

16

7/22/2019 Makri Dou 2009

17/96

2.2 (Gichard L. D. et al. 2006).

&

.

.

17

7/22/2019 Makri Dou 2009

18/96

7/22/2019 Makri Dou 2009

19/96

3.1.2

(Ipp et al.,1989). ACIP

.

,

..

(Bergeson et al,.1982) .

. 3 5

(Beyea & Nicoll, 1995).

. 25-38

2ml.

3.1.3

(Beecroft & Redick 1990, Hahn 1990, Covington & Trattler 1997).

.

2 , .

.

.

( .,2003).

2-5ml 38

.

. H

,

(Zelman,1961).

19

7/22/2019 Makri Dou 2009

20/96

(Kozier et al.,1993). ... 12%

(Farley,1986).

3.2:

3.1.4

,

.

,

(Bolander 1994, Rosdah 1995).

.

(Bolander,1994).

20

7/22/2019 Makri Dou 2009

21/96

3.3:

3.2

.

.

.

.

.

.

. 22-27

, 18-25 .

. 0,5ml

.(Zenk,1982,1993)

.

.(Hahn,1990,McConnell,1982)

21

7/22/2019 Makri Dou 2009

22/96

,

,.

3.2.1

Nisbet A. (2006)

100 .12

35 ,

, 26 25 .,

. 43

35 ., 72 25 .

.

.

,

, ,

. ,

.

,

. ,

22

7/22/2019 Makri Dou 2009

23/96

3.1

,

,

(., 2003 )

3.3

3.3.1

. ,

. ,

.

.(Haber et al. 2000, Hochstetter1954,1955,1956)

, (Hanson,1963).

.

23

7/22/2019 Makri Dou 2009

24/96

.

(Kruszewski et al,1979).

. 5-8cm

(Berger & Williams,1992, Murphy,1991).

3.3.2

.. ,

.

Jablecki (2000) ,

. , 2 3 .

,

.

(Light & Perl, 1993). Jablecki (2000)

. Barnhill, Holbert, Jackson & Erickson (1996)

10

, 93

.

.

.

90

.(Belanger-Annable 1985, Dickerson 1992, Gros-wasser 1997, McConnell 1982)

.

72-90 (Katsma D. & Katsma R.,2000). , 72-

24

7/22/2019 Makri Dou 2009

25/96

90 .

.

. .

. (Workman,1999)

3.4:

, 10 ml

(Zelman,1961).

.

10

(-). (Hahn 1990, Stokes et al. 1944, Zelman 1961).

25

7/22/2019 Makri Dou 2009

26/96

-:

.

(Beyea & Nicholl 1995)

, (Keen 1986).

( 3.4)

1 2cm.

,

. ,

,

, .

.

10 .

, .

.

(Beyea & Nicholl 1995).

26

7/22/2019 Makri Dou 2009

27/96

3.3.3

E.

.

,

,

(Beyea & Nicholl 1995). ,

( )

(MacGabhann 1998, Quartermaine & Taylor 1995)

- ,

. Quartermaine Taylor (1995)

- , MacGabhann (1998)

.

(Chaplin et al. 1985).

. ,

,

,

.

3.3.4.

2-4 (Roberts,1975).

.

.

27

7/22/2019 Makri Dou 2009

28/96

4

.

, . : ,

, , , ,

, ,

.O

. ,

. (Small S.P. 2004)

4.1

.

(Workman B. 1999).

4.1,4.2: 10 x 6

28

7/22/2019 Makri Dou 2009

29/96

4.1.1

.

, , .

.

.

. , ,

.

.

, ,

(Wounds 2003).

4.3:

.

29

7/22/2019 Makri Dou 2009

30/96

4.1.2

.

.

.

.

, ,

.

.

(Wounds 2003).

4.4:

30

7/22/2019 Makri Dou 2009

31/96

4.2

.. ,

(Chung J. et al. 2001).

.

,

.

Torrance (1989) :

.

.

.

.

.

.

4.3

,

(Pollilio & Kiley 1997). ,

.

31

7/22/2019 Makri Dou 2009

32/96

4.4

,

, .

.

.

, .

,

,

(Small S.P. 2004).

, , (

).

: , , ,

.

, o. ,

(Small S.P. 2004).

.

.

.

.(Pandian et al. 2006)

32

7/22/2019 Makri Dou 2009

33/96

4.5

.

. .

,

(Cheng J. & Abdi S. 2007).

. : )

, ) )

(Wounds 2003).

4.5:

33

7/22/2019 Makri Dou 2009

34/96

4.6 -

.

.

.

.

.

(Wounds 2003).

4.7

C (HBV,HCV), HIV, Ebola Lassa (Simonsen L. et al.1999).

,

, , , ,

, .

.

. ,

o

,

, .

34

7/22/2019 Makri Dou 2009

35/96

,

, , , , ,

, (Kermode M. 2004).

. ,

.

,

.

.

,

.

,

.

, ,

.

, ,

.

,

.,

(Simonsen L. et al.

1999).

35

7/22/2019 Makri Dou 2009

36/96

4.8

:

,

( ).

,

,

. Kozier et al. (1993)

,

. ,

5-7.5

(DuGas & Knor 1995, Perry &

Potter 1998).

:

(Greenblatt & Allen

1978) . ,

, ,

,

.,

.

2 mL .

( 2 mL) ,

. (

) ,

(0.5-2 mL ),

(Cocoman A. & Murray J. 2008).

36

7/22/2019 Makri Dou 2009

37/96

:

,

(Zelman 1961).

,

(Muller-Vahl 1985)

. Winslow (1996)

.

(Farley et al. 1986)

. , (Michaels & Poole

1970),

(Zelman 1961), ,

.

:

,

.

-

. ,

(Cocoman A. & Murray J. 2008).

4.9

.

,

.

. , ,

,

(Cheng J. & Abdi S. 2007).

37

7/22/2019 Makri Dou 2009

38/96

,

(Beyea & Nicholl 1995).

- (Burden 1994).

, ,

.

- (-track)

(Beyea & Nicholl

1995).

(Springhouse Corporation 1993).

,

(Pollilio Kiley 1997).

1) ,

.

2)

, , .

38

7/22/2019 Makri Dou 2009

39/96

3) ,

(

).

4)

.

5) ,

.

6)

, .

7) - (-track).

8) .

9) ,

90 ,

.

10) : 1ml

.

11)

.

12) ,

. (Workman B. 1999)

39

7/22/2019 Makri Dou 2009

40/96

5

5.1

12 .

5%

, .

0.9

8.5 1.5 (Lala K. &

Lala M. 2003)

26.294 Boston

Collaborative Drug Surveillance Program, (

,) 46% .

80%

: G , ,

, , colistimethate sodium,

, , , , ,

(Greenblatt DJ & Allen MD 1978).

, (WHO 1998).

o ,

-

.

0.9 8.5

1.5 . , ,

40

7/22/2019 Makri Dou 2009

41/96

, ,

25% 96%.

.

1997

10 .

500

: 20

120 .

65

. (Simonsen L. et al.1999).

,

, , IV .

5.2

1987 -1998 .

19

. 14 50

. , 20

> 31

.

, 50

. ,

31 >90

. (Simonsen L. et al.1999).

.

41

7/22/2019 Makri Dou 2009

42/96

5% , 95%

.

20% 80%

.

30

.(Simonsen L. et al.1999).

5.2.1

,

..

,

. ,

,

, (Kermode . 2004).

1) .

2) .

3) .

4) ,

(

).

5)

.

42

7/22/2019 Makri Dou 2009

43/96

6)

.

7) .

8) , .

9)

.

10) .

11)

.

12) ,

.

13)

.

14)

.

15) .

16) .

17) .

43

7/22/2019 Makri Dou 2009

44/96

5.3

66 , 70

.

, 82

.

96

, .

85 99

. ,

: .

, ,

(Simonsen L. et al.1999).

5.4

5.4.1

,

. ,

.

66

, 1990 2003 36 (55%)

,29 (44%) (1%) . 57 (86%),

44

7/22/2019 Makri Dou 2009

45/96

. ,

(Pandian et al. 2006).

:

, 41 (62%) , 23 (35%) , 7 (11%) , 34

(52%) , 22 (33%).

59 (89%) 7 (11%) .

8.5 22.9 .

(p < 0.02) (p